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Recently, new chemotherapy agents which target the non-structural components of mitosis have been
developed. An important protein involved in several mitotic phases is the Aurora-A protein. By means of the
phosphorylation of different substrates, Aurora-A regulates the correct development of the various phases of
mitosis. The kinase activity of this protein makes Aurora-A an excellent candidate as an oncogene. The first data
of Aurora-A involvement in cancer regarded the identification of Aurora-A overexpression in primary breast and
colon tumour samples. With regard to the predictive role of Aurora-A, it has been shown that its overexpression
disrupts the spindle checkpoint activated by paclitaxel (Taxol) or nocodazole treatment, thus inducing the
cells to become resistant to these drugs. The development therefore of small molecules with an Aurora-A
inhibition function may make it possible to reduce or block the oncogenic activity of Aurora-A and in addition
may improve the survival of oncological patients showing resistance to paclitaxel or nocodazole treatment.
Three novel Aurora kinase inhibitors have recently been described—Hesperadin, ZM447439 and VX-680. All
these three drugs have been designed to target the ATP-binding site of Aurora kinase, so they inhibit all three
Aurora kinase family members showing a similar phenotype when tested in cell-based assays. Among these
three different molecules, VX-680 has shown promising results in in vitro and in vivo studies. In conclusion, it
is clear that we are entering a new era in anti-mitotic therapy with the identification and now clinical translation
of new targets in mitosis beyond tubulin but many questions remain with regard to Aurora function.
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introduction
The process of cell division, mitosis, is a multiphase mechanism
by which the duplicate DNA is completely segregated into two
daughter cells. The main effectors of this division are the
mitotic spindle and the centrosomes, two structures made up of
microtubules which cooperate in the process of chromosome
condensation, alignment on the metaphase plate and
segregation. In a tumoral cell, aberrations of these processes
generate aneuploid daughter cells with genomic instability and
make it possible for apoptosis to occur. For this reason, several
chemotherapy agents, such as vinca alkaloids and taxanes, have
been developed and are currently used in clinical cancer
treatment. The principal target of these agents is the tubulin,
the main protein present in the mitotic spindle and in the
centrosomes. These drugs usually induce stabilisation or
destabilisation of the mitotic spindle structure and block the
deregulated mitotic process of the tumoural cells.
Recently, new chemotherapy agents which target the non-
structural components of mitosis have been developed. Each
phase of mitosis is, in fact, regulated by the presence of several
mitotic kinesins and protein kinases that synchronise all phases
and produce tumoural cells. For instance, the mitotic kinesin
spindle protein (KSP) is important for the regulation of mitotic
spindle bipolarity by conducting centrosome separation and
the use of KSP inhibitors induces apoptosis in some tumour
cell lines [1, 2]. The centromeric protein E is involved in
chromosome congression at the metaphase and its inhibitors
are now in preclinical development [3]. Finally, Polo-like
kinase 1 is required for centrosome maturation and the
formation of the mitotic spindle and the use of small molecules
or small interfering RNA have shown interference in several
mitosis stages [4, 5].
the Aurora-A
Another important protein involved in several mitotic phases is
the Aurora-A protein also known as serine threonine kinase
15 (STK15), BTAK, Aurora kinase A, Aurora-2 or AIKI. This
gene is a member of the Aurora kinase family made up of
Aurora-A, B and C and is conserved throughout eukaryotic
evolution. Human Aurora-A is located at chromosome
20q13.2, which is commonly amplified in several tumoural
tissues [6–13]. The protein structure of the Aurora-A is based
on a variable amino terminal regulatory domain, with three
s
y
m
p
o
s
iu
m
a
rt
ic
le
*Correspondence to: Antonio Russo, MD. Section of Medical Oncology, Department of
Surgery and Oncology, Universita` di Palermo, Via del Vespro 127, 90127 Palermo, Italy.
Tel: +39-091-6552500; Fax: +39-091-6554529; E-mail: lab-oncobiologia@usa.net
Both authors have contributed equally to this work.
ª 2007 European Society for Medical Oncology
putative Aurora boxes (A-box I, II and III), and a conserved
carboxyl terminal catalytic domain, with an activation motif
and a destruction box [14]. The functional significance of the
three A-boxes is not fully understood but there is some
evidence that they may be related to subcellular localisation or
substrate recognitions. Aurora-A is a serine–threonine kinase
which requires phosphorylation in order to become activated.
The presence of three phosphoric groups, respectively, at
residues serine 51, threonine 288 and serine 342 of the
activation motif is particularly important for the function of
this kinase. The serine 51 residue is involved in controlling the
timing of Aurora-A destruction process during mitotic exit
while the threonine 288 is relevant for the kinase activity.
The T288D mutation, in fact, which mimics a constitutive
phosphorylation status, gives rise to the presence of
a constitutively active Aurora kinase. Finally, the serine 342
residue is principally involved in the maintenance of its
conformational three-dimensional structure [14].
The levels of Aurora-A are usually regulated during the cell
cycle phases by means of two different processes, ubiquitin-
dependent proteolysis [15, 16] and phosphorylation/
dephosphorylation events [17]. Aurora-A, in fact, is
ubiquitinated by the anaphase-promoting complex/cyclosome
(APCCDH1) through the interaction with the destruction box
(D-box) and the serine 51 residue of the A-box II. Moreover,
a novel protein known as Aurora-A kinase-interacting protein
seems to regulate the Aurora-A degradation through the
proteasome-dependent pathway [18]. The mechanism of
feedback regulation through phosphorylation/
dephosphorylation events during the cell cycle is, instead,
mediated by the action of kinase and protein phosphatase
1 [19].
the Aurora-A protein in mitotic events
During the late-G2 to M phase, the Aurora-A levels and kinase
activity increase in order to be able to perform the role of
guardian of the poles’. By means of the phosphorylation of
different substrates, in fact, Aurora-A regulates the correct
development of the various phases of mitosis, including
centrosome maturation and separation, mitotic entry, bipolar
spindle assembly, chromosome alignment on the metaphase
plate and cytokinesis [20] (Figure 1). In human cell lines,
Aurora-A depletion results in the inhibition of both
centrosome maturation [21] and centriole pairs separation
[22]. The regulation of these two phases of mitosis occurs by
means of the phosphorylation, respectively, of the transforming
acidic coiled-coil (TACC) proteins, which cooperate in the
growth of the microtubules at both the minus and the plus
ends, and of the kinesin-like motors, needed for centrosome
separation during the prometaphase.
The commitment of cells to mitosis in the late G2 phase
involves the activation of both Aurora-A and CDK1–cyclin B.
This activation is a kind of feedback mechanism in which the
Aurora-A activation requires the CDK1–cyclin B activation
[23] and the CDK1–cyclin B complex is activated by the
Aurora-A-dependent phosphorylation of CDC25B at serine
Figure 1. (A) Aurora-A is first detected in late G2 phase at the centrosome, where it is involved in the commitment to mitosis (1) and in maturation of
centrosome through the phosphorylation of TACC (2). (B) Aurora-A is required for the separation of centrosomes in prometaphase through the activation
of the kinesin-like motors (3). (C) For the bipolar spindle assembly (4). (D) Aurora-A cooperates with Aurora-B in the activation and maintenance of
CENP-A (5), allowing a correct chromosome alignment on the metaphase plate.
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353, the phosphatase involved in cyclin-dependent activation
[21].
Aurora-A protein regulates bipolar spindle assembly by
means of the interaction with the TPX2 protein, which is both
a substrate and an activator of Aurora-A. Experiments
conducted singly on Aurora-A and TPX2 depletion, in fact,
have shown in both these the formation of multipolar spindles
[20, 24].
Several data reported in literature have shown that the
chromosome alignment on the metaphase plate is principally
regulated by the Aurora-B protein [25–27]. Recent studies [28]
have shown that both Aurora-A and Aurora-B are involved in
this step by means of the phosphorylation at the serine
7 residue of the CENP-A, the protein responsible for the
interaction between microtubules and the kinetochore. More
specifically, Aurora-A is responsible for the first CENP-A
phosphorylation and activation while Aurora-B is responsible
for maintaining this activation status from the late prophase
to the metaphase.
A perfect timing of Aurora-A activation and destruction is
necessary for a proper cytokinesis. Both Aurora-A
overexpression and inhibition, in fact, lead to multinucleated
cell formation [29–33]. Finally, since the dephoshorylation of
several Aurora-A substrates occurs, as previously mentioned,
through Aurora-A degradation in an APCCDH1-dependent
manner, this represents a key event in the completion of
cytokinesis [16].
Aurora-A and cancer
The first data of Aurora-A involvement in cancer regarded the
identification of Aurora-A overexpression in primary breast
and colon tumour samples [34, 35]. Subsequently, several other
studies showed chromosome 20q13 amplification or Aurora-A
overexpression in many different tumour types including
breast, pancreatic, ovarian and gastric cancers [6–13].
Furthermore, conflicting data have been reported regarding
Aurora-A overexpression and tumour grade. In fact, whereas
some authors suggest that Aurora-A overexpression is an early
pathological event in cancer progression both in animal models
[36] and in patients affected by ovarian cancer [11], others
indicate a significant association with higher grade tumours
and poor prognosis [37].
Mitosis is an extremely important biological event regulated
by Aurora-A, and this fact together with the kinase activity of
this protein makes Aurora-A an excellent candidate as an
oncogene. Several studies have, in fact, reported a specific role
of Aurora-A in cancer development and progression. For
instance, unlike normal cells, in tumour cells Aurora-A
expression may be detected diffusely in all the cytoplasm [11],
giving rise to aberrant phosphorylated cytoplasmic proteins.
A large number of studies taking into consideration the kinase
activity of the protein have reported a relationship between
Aurora-A, the p53 tumour suppressor protein and cancer
progression [38–40]. Aurora-A, in fact, phosphorylates p53
at the serine 215 residue, inducing an inactivation of
transactivation activity, and at the serine 315 residue,
facilitating MDM2-mediated p53 degradation. Moreover, an
association has been shown between Aurora-A overexpression,
p53 mutational status and a worse prognosis in patients
affected by hepatocellular carcinomas [37]. Finally, cells with
Aurora-A overexpression and with a non-functional post-
mitotic G1 checkpoint are usually tetraploid [29, 30].
With regard to the predictive role of Aurora-A, it has been
shown that its overexpression disrupts the spindle checkpoint
activated by paclitaxel (Taxol) or nocodazole treatment,
thus inducing the cells to become resistant to these drugs
[30, 41]. The development therefore of small molecules with
an Aurora-A inhibition function may make it possible to
reduce or block the oncogenic activity of Aurora-A and in
addition may improve the survival of oncological patients
showing resistance to paclitaxel or nocodazole treatment.
Aurora-A kinase inhibitors
In the last few years, several drugs with an inhibition action
towards Aurora-A kinase have been developed and several
protein kinase inhibitors, already present in other preclinical
studies, have been tested to assess the specificity to Aurora-A.
The identification of Aurora-A inhibitors may require
the choice of two different approaches—blocking the
protein–protein interaction between Aurora-A and cofactor
or substrates or blocking the ATP-binding site of the serine
threonine kinase. Most of the small molecules with Aurora-A
inhibitor function identified so far show good specificity for
the ATP-binding site but less for the target protein and this
may be a problem if all the protein kinases involved in mitosis
are taken into consideration. This difficulty increases in the
presence of an Aurora kinase family where the action of each
member during mitosis may be overlapped and is not yet fully
understood. Even if Aurora-A is considered the principal
member of the family with oncogenic activity, therefore, it
may well be that the anticancer action of some chemotherapy
agents do not reflect the blocking activity on Aurora-A but on
other family members (mainly Aurora-B) or protein kinase. For
this reason, we will refer to these small molecules as Aurora
kinase family inhibitors instead of specifying their role towards
the Aurora-A protein. An explanation of the effects of the
inhibition action of these small molecules is now possible. In
the presence, in fact, of an anti-Aurora compound, which
inhibits both Aurora-A and Aurora-B, the abnormal spindles
arising from the lack of Aurora-A activity might not be visible
because the absence of Aurora-B activity will not trigger mitotic
arrest and cytokinesis. Thus the only phenotype that will be
observed will look similar to the one observed after Aurora-B
down-regulation. Table 1 shows the main Aurora kinase
inhibitors which have already undergone preclinical or phase
I/II clinical trials. Unfortunately, very few data are available
since a great many of these molecules are in still in the
experimental phase of each study.
Aurora kinase inhibitors in preclinical
studies
The JNJ-7706621 molecule is a [1,2,4]triazole-3,5-diamine with
a dual inhibitor effect on cyclin-dependent kinases and Aurora
kinase family members but with a unique inhibitor profile [42].
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In more specific terms, the treatment of human cancer cells
with this molecule induces a cell growth inhibition independent
of p53, pRB and P-glycoprotein status; apoptosis activation and
the reduction of colony formation while in human tumour
xenograft models several dosing schedules with an
antitumoural activity have been identified. Furthermore, it has
been shown that JNJ-7706621 treatment at low concentrations
induces a slowing down of cell growth, while at high
concentrations, it leads to cytotoxicity. With regard to the
JNJ-7706621 effect on the Aurora kinase family member,
preliminary studies have shown that the treatment of cells with
this molecule induces endoreduplication and loss of histone
H3 phosphorylation, all consequences of Aurora kinase and
particularly of Aurora-B inhibition.
The PHA-680632 molecule, a novel Aurora kinase inhibitor,
shows an anticancer activity on a wide range of different cancer
cell lines and on different animal tumour models at well-
tolerated doses. In this case, too, the effect of this anticancer
activity on cancer cells is reported as the inhibition of the
histone H3 phosphorylation at the serine 10 residue.
Aurora kinase inhibitors in clinical
studies
Unfortunately, most of the Aurora kinase inhibitors showing
a positive response in preclinical studies and which at present
are being analysed in clinical studies are in early-phase trials
and no specific information is available at this time.
Until now, knowledge regarding the mechanism of action
of protein kinase inhibitors has mainly involved the final effect
on mitosis and not on the different substrates. For this reason,
several studies have been conducted in order to investigate
whether or not selective kinase inhibitors involved in other
biological events may have an effect on Aurora proteins.
For example, experiments regarding chemical proteomics have
shown that the molecule SU6668, originally designed as an
inhibitor of receptor tyrosin kinases implicated in tumour
vascularisation, also has the Aurora kinases as substrate [43].
The observation, therefore, that SU6668 treatment of HeLa cells
leads to a reversible G2–M block consistent with Aurora
inactivation may make it possible to develop future strategies
for more efficient therapeutic intervention in cancer based on
both receptor tyrosine kinase (RTKs), involved in tumour
vascularisation, and Aurora kinases, involved in mitotic
progression targeting.
Three novel Aurora kinase inhibitors have recently been
described—Hesperadin [26], ZM447439 [25] and VX-680 [44].
Hesperadin in particular has a structure similar to the
SU6668 molecule, ZM447439 is the first inhibitor to be
characterised and VX-680 is the first Aurora kinase inhibitor to
enter clinical trials. All these three drugs have been designed to
target the ATP-binding site of Aurora kinase, so they inhibit all
three Aurora kinase family members showing a similar
phenotype when tested in cell-based assays. Among these three
different molecules, VX-680 has shown promising results in
in vitro and in vivo studies. In vitro VX-680, in fact, blocks
cell proliferation, disrupts bipolar spindle formation, causes
accumulation of cells with 4N or greater DNA and eventual cell
death while in vivo it is able to cause regression in xenograft
models of leukaemia and colon cancer (Hl-60 and HCT-116) at
well-tolerated doses [44]. Moreover, VX-680 has no effect on
non-cycling primary human cells, probably because expression
and activity of Aurora kinases is low in normal cells and this
makes this molecule a promising anticancer drug. Finally,
various protracted intravenous infusions have been tested in
phase I trials for patients with solid and haematological
malignancies. The main dose-limiting toxicity in the solid
tumour study was neutropoenia. Unlike other anti-mitotic
agents such as taxanes, it seems that the main dose-limiting
toxicity for VX-680 is neutropoenia and no significant clinical
neuropathy has been observed.
A study of the crystal structure of VX-680 bound to Aurora-
A shows the potency and selectivity profile of this molecule.
Cheetam Harrington and co-workers have, in fact,
demonstrated that VX-680 weakly binds Aurora-A open active
conformation and subsequently traps the enzyme in a closed
inactive conformation by binding and stabilising the
hydrophobic activation loop [44]. The high degree of selectivity
of VX-680, therefore, depends on the fact the Aurora kinases
are able to adopt a closed conformation while other protein
kinases are not.
The effect of longer exposure to these three Aurora kinase
inhibitors is different according to the p53-dependent post-
mitotic checkpoint status [25, 45]. P53, in fact, is able to
respond to a failed cell division inducing a G1-like arrest as
a sort of back up to the spindle checkpoint arrest. Thus, the
cell lines with a wild-type or active p53 underwent apoptosis or
arrest in a pseudo-G1 phase while the cell lines with a mutated
or inactive p53 became polyploid.
In contrast to Aurora-B inhibition, Aurora-A inhibition
causes a delay and not a block in mitotic entry and
a chromosome alignment that is found in aneuploid cells
[22]. In this case, the Aurora-A inhibitors may have an
oncogenic effect generating chromosome instability. Thus,
even though the Aurora kinase inhibition brought about by
these different drugs has shown primary results in cancer
treatment, it might well be that the chromosome instability
induced by them will generate aberrant mitotic events that
promote tumorigenesis. The mechanisms and signalling
cascades by which Aurora-A inhibitors induce cell death
must therefore be clarified.
Table 1. Main Aurora kinase inhibitors which have already undergone
preclinical or phase I/II clinical trials
Preclinical Phase I Phase II
CHR-3520 PHA-739358 VX-680
CTK-110 AT-9283
CYC-116 MLN-8054
ENMD-981693 R-763
JNJ-7706621 SU6668
PHA-680632 Hesperadin
SNS-314 ZM447439
MP-529
MP-235
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conclusions
The principal goal in the development of Aurora kinase
inhibitors is to assess whether or not the administration of
these small molecules to patients will yield a clinical benefit.
For this reason it is essential to answer several different
questions such as those regarding the effect of these inhibitors
on other kinase proteins, the effect of the same drugs on the
three different members of the Aurora kinase family and the
pathways and the protein involved in Aurora kinase inhibition.
For example, the interaction between Aurora kinase and p53
might indicate a patient’s inclusion in the study according to
the p53 status. Furthermore, it will be important to identify
the safe dose for target inhibition in humans, the tumour types
that most likely respond to these drugs, the reversibility of the
effect on normal cells and the dependence of this on dose and
duration of exposure, the toxicity effects observed in patients,
the effect of these drugs on disease-free survival and overall
survival and the effect of these drugs when used in combination
with other chemotherapy agents, in particular, those which
depend on the spindle checkpoint such us taxanes and others.
In conclusion, it is clear that we are entering a new era in
anti-mitotic therapy with the identification and now clinical
translation of new targets in mitosis beyond tubulin but many
questions remain with regard to Aurora function and the
answers will be of great interest, not only to basic researchers
but also to clinicians and patients.
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